Nephros Stock Performance
| NEPH Stock | USD 4.68 0.02 0.43% |
The company secures a Beta (Market Risk) of -0.25, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Nephros are expected to decrease at a much lower rate. During the bear market, Nephros is likely to outperform the market. At this point, Nephros has a negative expected return of -0.0405%. Please make sure to verify Nephros' semi variance, and the relationship between the maximum drawdown and accumulation distribution , to decide if Nephros performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Nephros has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Nephros is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return 0.43 | Five Day Return 5.64 | Year To Date Return (1.47) | Ten Year Return 33.33 | All Time Return (99.56) |
Last Split Factor 1:9 | Dividend Date 2019-07-10 | Last Split Date 2019-07-10 |
1 | Acquisition by Daron Evans of 1111 shares of Nephros at 2.7 subject to Rule 16b-3 | 10/28/2025 |
2 | Could The Market Be Wrong About Nephros, Inc. Given Its Attractive Financial Prospects | 11/13/2025 |
3 | Is Nephros Inc. stock a buy before earnings results - Portfolio Return Summary Risk Adjusted Buy and Sell Alerts - newser.com | 11/20/2025 |
4 | Nephros enters license and supply agreement with Medica S.p.A. - SEC filing - MarketScreener | 11/26/2025 |
5 | Income Plays Will Nephros Inc stock sustain high P E ratios - Market Risk Summary Fast Entry and Exit Trade Plans - B NI V | 12/02/2025 |
6 | 3 Promising Penny Stocks With Market Caps Up To 400M | 01/21/2026 |
| Begin Period Cash Flow | 4.3 M | |
| Total Cashflows From Investing Activities | -50 K |
Nephros Relative Risk vs. Return Landscape
If you would invest 542.00 in Nephros on October 26, 2025 and sell it today you would lose (74.00) from holding Nephros or give up 13.65% of portfolio value over 90 days. Nephros is currently does not generate positive expected returns and assumes 6.4934% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Nephros, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nephros Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nephros' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nephros, and traders can use it to determine the average amount a Nephros' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Based on monthly moving average Nephros is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nephros by adding Nephros to a well-diversified portfolio.
Nephros Fundamentals Growth
Nephros Stock prices reflect investors' perceptions of the future prospects and financial health of Nephros, and Nephros fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nephros Stock performance.
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0764 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 45.72 M | ||||
| Shares Outstanding | 10.63 M | ||||
| Price To Earning | (4.51) X | ||||
| Price To Book | 4.97 X | ||||
| Price To Sales | 2.77 X | ||||
| Revenue | 14.16 M | ||||
| Gross Profit | 11.34 M | ||||
| EBITDA | 227 K | ||||
| Net Income | 74 K | ||||
| Cash And Equivalents | 4.18 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 1.41 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 5.27 X | ||||
| Book Value Per Share | 0.94 X | ||||
| Cash Flow From Operations | (492 K) | ||||
| Earnings Per Share | 0.14 X | ||||
| Market Capitalization | 49.73 M | ||||
| Total Asset | 11.21 M | ||||
| Retained Earnings | (144.33 M) | ||||
| Working Capital | 6.74 M | ||||
| Current Asset | 1.53 M | ||||
| Current Liabilities | 684 K | ||||
About Nephros Performance
By evaluating Nephros' fundamental ratios, stakeholders can gain valuable insights into Nephros' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nephros has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nephros has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 201.81 | 305.50 | |
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.01 | 0.01 |
Things to note about Nephros performance evaluation
Checking the ongoing alerts about Nephros for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nephros help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nephros generated a negative expected return over the last 90 days | |
| Nephros has high historical volatility and very poor performance | |
| Nephros is unlikely to experience financial distress in the next 2 years | |
| Nephros currently holds about 4.18 M in cash with (492 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Nephros has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Why Medicus Pharma Ltd. stock could rally in 2025 - GDP Growth Short-Term High Return Strategies - ulpravda.ru |
- Analyzing Nephros' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nephros' stock is overvalued or undervalued compared to its peers.
- Examining Nephros' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nephros' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nephros' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nephros' stock. These opinions can provide insight into Nephros' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Nephros Stock analysis
When running Nephros' price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |